Perifosine as a potential novel anti-telomerase therapy

Brody Holohan, Moriah M. Hagiopian, Tsung Po Lai, Ejun Huang, Daphne R. Friedman, Woodring E. Wright, Jerry W. Shay

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Most tumors circumvent telomere-length imposed replicative limits through expression of telomerase, the reverse transcriptase that maintains telomere length. Substantial evidence that AKT activity is required for telomerase activity exists, indicating that AKT inhibitors may also function as telomerase inhibitors. This possibility has not been investigated in a clinical context despite many clinical trials evaluating AKT inhibitors. We tested if Perifosine, an AKT inhibitor in clinical trials, inhibits telomerase activity and telomere maintenance in tissue culture and orthotopic xenograft models as well as in purified CLL samples from a phase II Perifosine clinical trial. We demonstrate that Perifosine inhibits telomerase activity and induces telomere shortening in a wide variety of cell lines in vitro, though there is substantial heterogeneity in long-term responses to Perifosine between cell lines. Perifosine did reduce primary breast cancer orthotopic xenograft tumor size, but did not impact metastatic burden in a statistically significant manner. However, Perifosine reduced telomerase activity in four of six CLL patients evaluated. Two of the patients were treated for four to six months and shortening of the shortest telomeres occurred in both patients' cells. These results indicate that it may be possible to repurpose Perifosine or other AKT pathway inhibitors as a novel approach to targeting telomerase.

Original languageEnglish (US)
Pages (from-to)21816-21826
Number of pages11
JournalOncotarget
Volume6
Issue number26
StatePublished - 2015

Fingerprint

Telomerase
Telomere
Telomere Shortening
Heterografts
Therapeutics
Clinical Trials
Cell Line
Phase II Clinical Trials
perifosine
Neoplasms
Maintenance
Breast Neoplasms

Keywords

  • CLL
  • Perifosine
  • Targeted therapy
  • Telomerase
  • Telomeres

ASJC Scopus subject areas

  • Oncology

Cite this

Holohan, B., Hagiopian, M. M., Lai, T. P., Huang, E., Friedman, D. R., Wright, W. E., & Shay, J. W. (2015). Perifosine as a potential novel anti-telomerase therapy. Oncotarget, 6(26), 21816-21826.

Perifosine as a potential novel anti-telomerase therapy. / Holohan, Brody; Hagiopian, Moriah M.; Lai, Tsung Po; Huang, Ejun; Friedman, Daphne R.; Wright, Woodring E.; Shay, Jerry W.

In: Oncotarget, Vol. 6, No. 26, 2015, p. 21816-21826.

Research output: Contribution to journalArticle

Holohan, B, Hagiopian, MM, Lai, TP, Huang, E, Friedman, DR, Wright, WE & Shay, JW 2015, 'Perifosine as a potential novel anti-telomerase therapy', Oncotarget, vol. 6, no. 26, pp. 21816-21826.
Holohan B, Hagiopian MM, Lai TP, Huang E, Friedman DR, Wright WE et al. Perifosine as a potential novel anti-telomerase therapy. Oncotarget. 2015;6(26):21816-21826.
Holohan, Brody ; Hagiopian, Moriah M. ; Lai, Tsung Po ; Huang, Ejun ; Friedman, Daphne R. ; Wright, Woodring E. ; Shay, Jerry W. / Perifosine as a potential novel anti-telomerase therapy. In: Oncotarget. 2015 ; Vol. 6, No. 26. pp. 21816-21826.
@article{961637a92be24432b98f6f8b29de157a,
title = "Perifosine as a potential novel anti-telomerase therapy",
abstract = "Most tumors circumvent telomere-length imposed replicative limits through expression of telomerase, the reverse transcriptase that maintains telomere length. Substantial evidence that AKT activity is required for telomerase activity exists, indicating that AKT inhibitors may also function as telomerase inhibitors. This possibility has not been investigated in a clinical context despite many clinical trials evaluating AKT inhibitors. We tested if Perifosine, an AKT inhibitor in clinical trials, inhibits telomerase activity and telomere maintenance in tissue culture and orthotopic xenograft models as well as in purified CLL samples from a phase II Perifosine clinical trial. We demonstrate that Perifosine inhibits telomerase activity and induces telomere shortening in a wide variety of cell lines in vitro, though there is substantial heterogeneity in long-term responses to Perifosine between cell lines. Perifosine did reduce primary breast cancer orthotopic xenograft tumor size, but did not impact metastatic burden in a statistically significant manner. However, Perifosine reduced telomerase activity in four of six CLL patients evaluated. Two of the patients were treated for four to six months and shortening of the shortest telomeres occurred in both patients' cells. These results indicate that it may be possible to repurpose Perifosine or other AKT pathway inhibitors as a novel approach to targeting telomerase.",
keywords = "CLL, Perifosine, Targeted therapy, Telomerase, Telomeres",
author = "Brody Holohan and Hagiopian, {Moriah M.} and Lai, {Tsung Po} and Ejun Huang and Friedman, {Daphne R.} and Wright, {Woodring E.} and Shay, {Jerry W.}",
year = "2015",
language = "English (US)",
volume = "6",
pages = "21816--21826",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "26",

}

TY - JOUR

T1 - Perifosine as a potential novel anti-telomerase therapy

AU - Holohan, Brody

AU - Hagiopian, Moriah M.

AU - Lai, Tsung Po

AU - Huang, Ejun

AU - Friedman, Daphne R.

AU - Wright, Woodring E.

AU - Shay, Jerry W.

PY - 2015

Y1 - 2015

N2 - Most tumors circumvent telomere-length imposed replicative limits through expression of telomerase, the reverse transcriptase that maintains telomere length. Substantial evidence that AKT activity is required for telomerase activity exists, indicating that AKT inhibitors may also function as telomerase inhibitors. This possibility has not been investigated in a clinical context despite many clinical trials evaluating AKT inhibitors. We tested if Perifosine, an AKT inhibitor in clinical trials, inhibits telomerase activity and telomere maintenance in tissue culture and orthotopic xenograft models as well as in purified CLL samples from a phase II Perifosine clinical trial. We demonstrate that Perifosine inhibits telomerase activity and induces telomere shortening in a wide variety of cell lines in vitro, though there is substantial heterogeneity in long-term responses to Perifosine between cell lines. Perifosine did reduce primary breast cancer orthotopic xenograft tumor size, but did not impact metastatic burden in a statistically significant manner. However, Perifosine reduced telomerase activity in four of six CLL patients evaluated. Two of the patients were treated for four to six months and shortening of the shortest telomeres occurred in both patients' cells. These results indicate that it may be possible to repurpose Perifosine or other AKT pathway inhibitors as a novel approach to targeting telomerase.

AB - Most tumors circumvent telomere-length imposed replicative limits through expression of telomerase, the reverse transcriptase that maintains telomere length. Substantial evidence that AKT activity is required for telomerase activity exists, indicating that AKT inhibitors may also function as telomerase inhibitors. This possibility has not been investigated in a clinical context despite many clinical trials evaluating AKT inhibitors. We tested if Perifosine, an AKT inhibitor in clinical trials, inhibits telomerase activity and telomere maintenance in tissue culture and orthotopic xenograft models as well as in purified CLL samples from a phase II Perifosine clinical trial. We demonstrate that Perifosine inhibits telomerase activity and induces telomere shortening in a wide variety of cell lines in vitro, though there is substantial heterogeneity in long-term responses to Perifosine between cell lines. Perifosine did reduce primary breast cancer orthotopic xenograft tumor size, but did not impact metastatic burden in a statistically significant manner. However, Perifosine reduced telomerase activity in four of six CLL patients evaluated. Two of the patients were treated for four to six months and shortening of the shortest telomeres occurred in both patients' cells. These results indicate that it may be possible to repurpose Perifosine or other AKT pathway inhibitors as a novel approach to targeting telomerase.

KW - CLL

KW - Perifosine

KW - Targeted therapy

KW - Telomerase

KW - Telomeres

UR - http://www.scopus.com/inward/record.url?scp=84941243573&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84941243573&partnerID=8YFLogxK

M3 - Article

C2 - 26307677

AN - SCOPUS:84941243573

VL - 6

SP - 21816

EP - 21826

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 26

ER -